Ipca Laboratories Ltd vs Lupin Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 13, 2026

Key Highlights

The Latest Trading Price of Ipca Laboratories Ltd is ₹ 1585 as of 12 Jun 15:30 . The P/E Ratio of Ipca Laboratories Ltd changed from 21.2 on March 2021 to 51.6 on March 2025 . This represents a CAGR of 19.47% over 5 yearsThe P/E Ratio of Lupin Ltd changed from 38.1 on March 2021 to 28.2 on March 2025 . This represents a CAGR of -5.84% over 5 years The Market Cap of Ipca Laboratories Ltd changed from ₹ 24137 crore on March 2021 to ₹ 38088 crore on March 2025 . This represents a CAGR of 9.55% over 5 yearsThe Market Cap of Lupin Ltd changed from ₹ 46318 crore on March 2021 to ₹ 92522 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Ipca Laboratories Ltd for the Mar '26 is ₹ 2482 crore as compare to the Dec '25 revenue of ₹ 2430 crore. This represent the growth of 2.13% The revenue of Lupin Ltd for the Mar '26 is ₹ 7615 crore as compare to the Dec '25 revenue of ₹ 7282 crore. This represent the growth of 4.57% The ebitda of Ipca Laboratories Ltd for the Mar '26 is ₹ 531.79 crore as compare to the Dec '25 ebitda of ₹ 571.19 crore. This represent the decline of -6.9% The ebitda of Lupin Ltd for the Mar '26 is ₹ 2494 crore as compare to the Dec '25 ebitda of ₹ 1949 crore. This represent the growth of 27.95% The net profit of Ipca Laboratories Ltd changed from ₹ 198.98 crore to ₹ 309.4 crore over 8 quarters. This represents a CAGR of 24.70% The net profit of Lupin Ltd changed from ₹ 805.54 crore to ₹ 1468 crore over 8 quarters. This represents a CAGR of 35.03% The Dividend Payout of Ipca Laboratories Ltd changed from 8.9 % on March 2021 to 15.59 % on March 2025 . This represents a CAGR of 11.86% over 5 yearsThe Dividend Payout of Lupin Ltd changed from 23.43 % on March 2021 to 13.79 % on March 2025 . This represents a CAGR of -10.06% over 5 years .

About Ipca Laboratories Ltd

Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments.
The products of the Company are now sold in over 100 countries across the globe.
The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market. Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries.

About Lupin Ltd

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments. Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited.
In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited.
In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar.

FAQs for the comparison of Ipca Laboratories Ltd and Lupin Ltd

Which company has a larger market capitalization, Ipca Laboratories Ltd or Lupin Ltd?

Market cap of Ipca Laboratories Ltd is 40,232 Cr while Market cap of Lupin Ltd is 104,829 Cr

What are the key factors driving the stock performance of Ipca Laboratories Ltd and Lupin Ltd?

The stock performance of Ipca Laboratories Ltd and Lupin Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ipca Laboratories Ltd and Lupin Ltd?

As of June 13, 2026, the Ipca Laboratories Ltd stock price is INR ₹1585.8. On the other hand, Lupin Ltd stock price is INR ₹2292.7.

How do dividend payouts of Ipca Laboratories Ltd and Lupin Ltd compare?

To compare the dividend payouts of Ipca Laboratories Ltd and Lupin Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.